Physician profile
Matthew J Smith
NPI 1609876507
$25,357.86
in general payments reported to CMS, 2019-2025
66 companies · $4,347 in 2025
The $4,347 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,866 · 2020: $2,874 · 2021: $3,721 · 2022: $3,542 · 2023: $3,718 · 2024: $4,289 · 2025: $4,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $60.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,292.99 |
| Education | $60.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,751.09 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $2,852.88 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $2,789.00 | 2019-2025 | |
| Amgen INC. | $1,724.82 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $1,692.82 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,303.44 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $1,198.49 | 2019-2025 | Trelegy Ellipta, Rotarix, Bexsero |
| Novo Nordisk INC | $1,119.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,077.22 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $631.08 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $568.49 | 2019-2025 | Camzyos, Eliquis |
| Mylan Specialty L.P. | $508.83 | 2019-2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $502.25 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $345.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $331.83 | 2020-2025 | Zoryve, Seglentis, Livalo |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.